# Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

> **NCT02965378** · PHASE2,PHASE3 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 43 (actual)

## Conditions studied

- FGFR1 Gene Amplification
- FGFR1 Gene Mutation
- FGFR2 Gene Amplification
- FGFR2 Gene Mutation
- FGFR3 Gene Amplification
- FGFR3 Gene Mutation
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC v7

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** FGFR Inhibitor AZD4547
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02965378
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2017-01
- **Final completion:** 2019-10
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2021-05-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02965378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02965378, "Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02965378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*